CA2423050A1 - Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase - Google Patents

Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase Download PDF

Info

Publication number
CA2423050A1
CA2423050A1 CA002423050A CA2423050A CA2423050A1 CA 2423050 A1 CA2423050 A1 CA 2423050A1 CA 002423050 A CA002423050 A CA 002423050A CA 2423050 A CA2423050 A CA 2423050A CA 2423050 A1 CA2423050 A1 CA 2423050A1
Authority
CA
Canada
Prior art keywords
amino
alkyl
group
compound
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002423050A
Other languages
English (en)
Inventor
Gee Hong Kuo
Peter Connolly
Catherine Prouty
Alan Deangelis
Aihua Wang
Linda Jolliffe
Steve Middleton
Stuart Emanuel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22879359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2423050(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2423050A1 publication Critical patent/CA2423050A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés de pyrazine inhibant l'activité de tyrosine kinase. Certains de ces dérivés sont des inhibiteurs sélectifs de tyrosine kinase du récepteur de facteur de croissance endothéliale. L'invention concerne également des formulations pharmaceutiques renfermant les dérivés décrits et des procédés relatifs à l'utilisation des formulations considérées comme agents antitumoraux et dans le traitement des cancers à tumeur solide, de l'angiogenèse, de la rétinopathie diabétique, de la polyarthrite rhumatoïde, de l'endométriose et du psoriasis.
CA002423050A 2000-09-20 2001-09-19 Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase Abandoned CA2423050A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23396800P 2000-09-20 2000-09-20
US60/233,968 2000-09-20
PCT/US2001/029175 WO2002024681A2 (fr) 2000-09-20 2001-09-19 Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase

Publications (1)

Publication Number Publication Date
CA2423050A1 true CA2423050A1 (fr) 2002-03-28

Family

ID=22879359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002423050A Abandoned CA2423050A1 (fr) 2000-09-20 2001-09-19 Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase

Country Status (14)

Country Link
US (1) US6710048B2 (fr)
EP (1) EP1330452B1 (fr)
JP (1) JP2004523474A (fr)
AR (1) AR035494A1 (fr)
AT (1) ATE415396T1 (fr)
AU (1) AU9458401A (fr)
CA (1) CA2423050A1 (fr)
DE (1) DE60136731D1 (fr)
DK (1) DK1330452T3 (fr)
ES (1) ES2315308T3 (fr)
HK (1) HK1054393B (fr)
PT (1) PT1330452E (fr)
TW (1) TWI254711B (fr)
WO (1) WO2002024681A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (fr) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Composés de succinimide hétérocyclique fondu et leurs analogies, modulateurs de la fonction de récepteur d'hormone nucléaire
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DE60228330D1 (de) * 2001-12-19 2008-09-25 Bristol Myers Squibb Co Kondensierte heterocyclische verbindungen und deren analoga; modulatoren der funktion von nukleären hormonrezeptoren
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1501514B1 (fr) * 2002-05-03 2012-12-19 Exelixis, Inc. Modulateurs de proteine-kinases et leurs methodes d'utilisation
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
US7015227B2 (en) * 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
GB0215775D0 (en) * 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
US20060293256A1 (en) * 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
SI1569907T1 (sl) * 2002-12-13 2016-06-30 Ym Biosciences Australia Pty Ltd Na nikotinamidu osnovani kinazni inhibitorji
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity
CA2517256C (fr) * 2003-02-26 2013-04-30 Sugen, Inc. Composes d'aminoheteroaryle utilises en tant qu'inhibiteurs de proteine kinase
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
CA2530389A1 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases
AU2004278382B2 (en) * 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2007512275A (ja) * 2003-11-24 2007-05-17 エフ．ホフマン−ラ　ロシュ　アーゲー ピラゾリルおよびイミダゾリルピリミジン
WO2005058876A1 (fr) * 2003-12-16 2005-06-30 Gpc Biotech Ag Derives de la pyrazine utilises en tant que composes efficaces contre les maladies infectieuses
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
EP1814856A1 (fr) * 2004-11-12 2007-08-08 Galapagos N.V. Composés hétéroaromatiques de l'azote qui se lient au site actif d'enzymes de type protéines kinases
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP1917244A2 (fr) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Composes guanidine a substitution hetaryl et utilisation en tant que partenaires de liaison pour des recepteurs de 5-ht5
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
WO2008070350A2 (fr) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Procédés et compositions liés aux enveloppements de déshydrons
WO2008138992A1 (fr) * 2007-05-16 2008-11-20 Bayer Cropscience Sa Dérivés fongicides phényl-pyrimidinyl-amino
WO2009037247A1 (fr) * 2007-09-17 2009-03-26 Neurosearch A/S Dérivés de pyrazine et leur utilisation en tant que modulateurs des canaux potassiques
KR100898037B1 (ko) * 2007-10-05 2009-06-01 한국화학연구원 금속촉매의 커플링반응에 의한 트리알킬피라진 유도체의제조방법
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
KR101906146B1 (ko) * 2009-08-17 2018-10-10 메모리얼 슬로안-케터링 캔서 센터 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법
US20120165306A1 (en) * 2009-09-04 2012-06-28 Barsanti Paul A Pyrazinylpyridines useful for the treatment of proliferative diseases
US20110185353A1 (en) * 2010-01-27 2011-07-28 Jack Matthew Mitigating Problems Arising From Incompatible Software
JP2013542967A (ja) * 2010-11-17 2013-11-28 ノバルティス アーゲー ３−（アミノアリール）−ピリジン化合物
JP2014506878A (ja) * 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
JP6116554B2 (ja) * 2011-07-07 2017-04-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんの処置のための置換されたアザ複素環
KR20220143164A (ko) 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
AR093580A1 (es) 2013-08-30 2015-06-10 Ptc Therapeutics Inc Inhibidores bmi-1 de pirimidina sustituidos
WO2015076800A1 (fr) * 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Inhibiteurs de bmi-1 à base de pyridine et de pyrazine substituées
KR102461419B1 (ko) 2014-05-13 2022-11-02 메모리얼 슬로안 케터링 캔서 센터 Hsp70 조정물질 및 이의 제조 및 이용 방법
JP7249950B2 (ja) 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物
GB201715414D0 (en) * 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
GB201715318D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
CN113164479A (zh) 2018-08-17 2021-07-23 Ptc医疗公司 用于治疗胰腺癌的方法
IL281765B2 (en) 2018-09-25 2024-04-01 Cardurion Pharmaceuticals Inc Aminopyrimidine compound
PT4182308T (pt) 2020-07-15 2024-12-04 Chiesi Farm Spa Derivados de piridazinil amino como inibidores de alk5
TW202229273A (zh) 2020-09-28 2022-08-01 美商卡都瑞恩醫藥有限責任公司 稠合雜芳基化合物及其作為CaMKII抑制劑之用途
AU2022351219A1 (en) 2021-09-21 2024-05-02 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4463448A1 (fr) 2022-01-11 2024-11-20 Chiesi Farmaceutici S.p.A. Dérivés pyridazinyl amino utilisés en tant qu'inhibiteurs d'alk5

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514400A (en) * 1981-10-26 1985-04-30 William H. Rorer, Inc. Cardiotonic 5-heteroaryl-pyridone
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
PT994875E (pt) 1997-06-30 2004-06-30 Targacept Inc Derivados de 3-piridil-1-aza-biciclo-alcano para a prevencao e tratamento de desordens do snc
JP2002519348A (ja) * 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
EP1219609B1 (fr) * 1999-09-16 2007-04-04 Tanabe Seiyaku Co., Ltd. Composes cycliques aromatiques azotes a six elements
CN1231473C (zh) 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪

Also Published As

Publication number Publication date
TWI254711B (en) 2006-05-11
WO2002024681A3 (fr) 2002-06-20
EP1330452B1 (fr) 2008-11-26
AR035494A1 (es) 2004-06-02
HK1054393B (en) 2009-08-28
JP2004523474A (ja) 2004-08-05
WO2002024681A2 (fr) 2002-03-28
US6710048B2 (en) 2004-03-23
HK1054393A1 (en) 2003-11-28
PT1330452E (pt) 2009-01-22
AU9458401A (en) 2002-04-02
US20030060629A1 (en) 2003-03-27
EP1330452A2 (fr) 2003-07-30
DE60136731D1 (de) 2009-01-08
ATE415396T1 (de) 2008-12-15
DK1330452T3 (da) 2009-03-16
ES2315308T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
CA2423050A1 (fr) Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
ES2536216T3 (es) Composiciones y métodos para modular la ruta de señalización de Wnt
KR102104144B1 (ko) 3-아릴-5-치환-이소퀴놀린-1-온 화합물 및 그의 치료적 용도
KR100563514B1 (ko) 헤테로고리 화합물 및 이를 유효성분으로 하는 항종양제
AU2017359023B2 (en) 3-substituted propionic acids as alpha v integrin inhibitors
CA2860765C (fr) Compose pyrazine carboxamide
JP7320823B2 (ja) プテリジノン誘導体のｅｇｆｒ阻害剤としての使用
JP2023527242A (ja) Ａｘｌ阻害剤であるピリミジン系化合物
BRPI0610184A2 (pt) composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
SK287426B6 (sk) Použitie derivátov 2-aminonikotínamidu, deriváty 2-aminonikotínamidu, farmaceutický prípravok s ich obsahom a spôsob ich prípravy
KR20210144853A (ko) 암 치료를 위한 n-헤테로방향족 아미드 유도체
EP3822263A1 (fr) Dérivé de quinazoline de type éther de biaryle
KR101335770B1 (ko) 사치환된 피리다진 헷지호그 경로 길항제
US20240398805A1 (en) Quinazoline derived compounds as egfr inhibitors and their uses thereof
AU2014320149A1 (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
JP7584623B2 (ja) キナーゼ阻害活性を有する化合物
AU2022235533A1 (en) Compounds useful as inhibitors of alcat 1
CN113710663A (zh) Myc家族原癌基因蛋白的调节剂
EP3985005A1 (fr) Composé cyclique fusionné en tant qu'inhibiteur double de fgfr et vegfr
KR20210045981A (ko) 삼중고리형 화합물
AU2001294584B2 (en) Pyrazine derivatives as modulators of tyrosine kinases
AU2022276958B2 (en) Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
WO2007018941A2 (fr) Composes
AU2001294584A1 (en) Pyrazine derivatives as modulators of tyrosine kinases
HK40108920A (en) Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued